ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease
Movement Disorders · 2025-11 · 40 (11) · 2445-2456
DOI: 10.1002/mds.70009 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 06.09.2025. Verfasst von Aleksandar Videnovic und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mass General Brigham, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Phototherapy, Sleep Wake Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Background
Light therapy (LT) in Parkinson's disease improves sleep. Specific LT parameters require further study, including optimal frequency.
Objectives
We aimed to determine if once‐ or twice‐daily bright white light therapy (BWLT) improves sleep. Secondary aims compared once‐weekly BWLT to twice‐daily dim red light therapy (DRLT) as controls, estimated effects on fatigue, and adherence.
Methods
A 16‐week, randomized, phase 2, sham‐controlled, dose‐selection trial to select the superior BWLT frequency based on change in Parkinson's Disease Sleep Scale‐2 (PDSS‐2), participant burden, and safety. Participants were randomized to 8 weeks of twice‐daily BWLT, once‐daily BWLT, once‐weekly BWLT, or twice‐daily DRLT. An improvement of ≥1.7 points in 8‐week change of PDSS‐2 by daily BWLT relative to either control warranted advancing to a phase 3 trial.
Results
A total of 150 participants were randomized (mean [SD], 67 [8.6] years; 57 [38%] female; PDSS‐2 17.1 [6.7]). Mean 8‐week change from baseline in PDSS‐2 score improved (twice‐daily BWLT −2.6 [95% CI: −4.4, −0.7]; once‐daily BWLT ‐1.5 [−3.3, 0.3]; once‐weekly BWLT −0.4 [−2.2, 1.4]; twice‐daily DRLT −1.8 [−3.6, 0.1]) but did not meet criteria for advancing. Mean 8‐week change from baseline in Parkinson's Disease Fatigue Scale (PFS‐16) score improved (twice‐daily BWLT −6.4 [−9.8, −3.0]; once‐daily BWLT −2.2 [−5.5, 1.1]; once‐weekly BWLT −0.5 [−3.9, 2.8]; and twice‐daily DRLT −3.8 [−7.3, −0.4]). Mean adherence to LT was 63%–86%.
Conclusions
ENLITE‐PD did not meet the criteria for advancing daily LT to a phase 3 trial. LT was safe and well‐tolerated with good adherence. Once‐weekly BWLT was a non‐inferior control compared with twice‐daily DRLT. © 2025 International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Mass General Brigham, Boston, Massachusetts, USA.
- Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Clinical Trials Statistical and Data Management Center, University of Iowa, Iowa City, Iowa, USA.
- National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA.
- Department of Neurology, University of Colorado, Aurora, Colorado, USA.
- Department of Neurology, Columbia University, New York, New York, USA.
ORCID-Profile: Aleksandar Videnovic, Hyun Joo Cho, Amy Amara, David Charles, Jason Margolesky, Carine Maurer, Nicolas Phielipp
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Videnovic, A., Coffey, C. S., Klerman, E. B., Cudkowicz, M., Cho, H. J., Amara, A., Marder, K., Zee, P., Desir, C., Ernst, H., Steinhart, E., Costigan, M., Gudjonsdottir, A., Klingner, E., Ecklund, D., Chase, M., Wang, A., Charles, D., Clifford, D., …, & Mosovsky, S. (2025). ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease. Movement Disorders, 40(11), 2445-2456. https://doi.org/10.1002/mds.70009
Vancouver
Videnovic A, Coffey CS, Klerman EB, Cudkowicz M, Cho HJ, Amara A, et al. ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease. Movement Disorders. 2025;40(11):2445-2456. doi:10.1002/mds.70009
BibTeX
@article{Videnovic2025,
author = {Videnovic, Aleksandar and Coffey, Christopher S and Klerman, Elizabeth B and Cudkowicz, Merit and Cho, Hyun Joo and Amara, Amy and Marder, Karen and Zee, Phyllis and Desir, Christina and Ernst, Holly and Steinhart, Erin and Costigan, Michelle and Gudjonsdottir, Anna and Klingner, Elizabeth and Ecklund, Dixie and Chase, Marianne and Wang, Amy and Charles, David and Clifford, David and Coleman, Juliana and Espay, Alberto J and Hung, Albert Y and Kadimi, Srinath and Killoran, Annie and Luo, Lan and Malkani, Roneil and Margolesky, Jason and Marsella, Jennifer and Maurer, Carine and Mihaila, Dragos and Moretti, Paolo and Park, Ariane and Phielipp, Nicolas and Sarva, Harini and Shah, Binit and Shill, Holly A and Siderowf, Andrew and Suski, Valerie and Tate, Jessica and Tse, Winona and Wyant, Kara and Zhang, Lin and Annis, Christine and Ambrogi, Katherine and Auerbach, Gabrielle and Benge, Melanie and Blystone, Emma and Brenner, Loraine and Aguilar, Carolina Burgos and Bwala, Grace and Dorsch, Juliana and Goude, Erica and Gutierrez, Hilda and Harper, Kelly and Hochberger, Samuel and Kalyani, Priyanka and Lamb, Jessica and Maupin, Kay and Molloy, Angela and Mosovsky, Sherri},
title = {ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease},
journal = {Movement Disorders},
year = {2025},
volume = {40},
number = {11},
pages = {2445--2456},
doi = {10.1002/mds.70009}
}
EUVIMED